# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

# C. Measurand:

# E. Applicant:

# G. Regulatory Information:

1. Regulation section: 21 CFR section 866.3330, Influenza virus serological reagents.

2. Classification: Class I

3. Product code: GNX

4. Panel:

Microbiology (83)

# H. Intended Use:

1. Intended use(s):

The ${ \mathrm { R A M P } } ^ { \mathrm { \textregistered } }$ Influenza A/B Assay is a qualitative immunochromatographic assay used to identify the presence of Influenza A and Influenza B nucleoprotein antigens in nasal wash, nasal aspirate, nasopharyngeal aspirate, and nasopharyngeal swab specimens from symptomatic patients. It is an in vitro diagnostic assay aids in the rapid differential diagnosis of influenza viral infections in symptomatic patients. A negative test is presumptive and it is recommended these results be confirmed by cell culture. Negative results do not preclude influenza virus infection and should not be used as the sole basis for treatment or other management decisions.

The test performance characteristics for Influenza B were established primarily with retrospective, frozen specimens. Users may wish to further evaluate the sensitivity performance of this test for Influenza B using fresh samples.

2. Indication(s) for use: Same as intended use.

3. Special conditions for use statement(s): For prescription use only.

4. Special instrument requirements: To be used only with the RAMP® 200 reader.

# I. Device Description:

The RAMP Influenza A/B Assay is a qualitative immunochromatographic test that utilizes the ${ \mathrm { R A M P } } ^ { \mathrm { \textregistered } }$ 200 reader for the differential determination of Influenza A and Influenza B in nasal wash/aspirate, nasopharyngeal aspirate, and nasopharyngeal swab samples. A wash/aspirate or swab sample is mixed with Sample Buffer using Assay Tip containing fluorescent-dyed latex particles coated with monoclonal antibodies targeting the Influenza A and B nucleoproteins, and applied into the sample well of the Test Cartridge. The sample migrates along the strip. Fluorescent-dyed latex (test) particles, coated with anti-Influenza A and anti-Influenza B nucleoprotein monoclonal antibodies bind to Influenza A or B nucleoprotein antigens, respectively, if present in the sample. As the sample migrates along the strip, Influenza-bound particles are captured at either the Influenza A or the Influenza B detection zone which is coated with either anti-Influenza A or anti-Influenza B nucleoprotein monoclonal antibodies, respectively. Excess fluorescent- dyed particles are captured at the internal standard zone. ${ \mathrm { R A M P } } ^ { \mathrm { \textregistered } }$ 200 reader then measures the amount of fluorescence emitted by the complexes bound at the two detection zones (Influenza A and Influenza B) and at the internal standard zone. The RAMP® 200 reader calculates a ratio (RAMP Ratio) of each influenza zone (A or B) fluorescence reading to the internal standard zone fluorescence reading. The reader compares these ratios to pre-defined threshold limits to determine a positive or negative result for Influenza A and Influenza B in the tested sample.

# J. Substantial Equivalence Information:

1. Predicate device name(s): BinaxNOW Influenza A & B Test

2. Predicate K number(s): (K062109)

3. Comparison with predicate:

<table><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">RAMP Influenza A/B Assay</td><td colspan="1" rowspan="1">BinaxNOW Influenza A &amp; BTest</td></tr><tr><td colspan="1" rowspan="1">Features/TechnicalInformation</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">The RAMP® Influenza A/B Assay is aqualitative immunochromatographicassay used with the RAMP® 200 readerto identify the presence of Influenza Aand Influenza B nucleoprotein antigensin nasal wash, nasal aspirate,nasopharyngeal aspirate, andnasopharyngeal swab specimens fromsymptomatic patients. It is an in vitrodiagnostic assay aids in the rapiddifferential diagnosis of influenza viralinfections in symptomatic patients. Anegative test is presumptive and it isrecommended these results be confirmedby cell culture. Negative results do notpreclude influenza virus infection andshould not be used as the sole basis fortreatment or other managementdecisions.</td><td colspan="1" rowspan="1">The BinaxNOW Influenza A &amp; B Testis an in vitro immunochromatographicassay for the qualitative detection ofInfluenza A and B nucleoproteinantigens in nasopharyngeal (NP)Swab, nasal swab, and nasalwash/aspirate specimens. It isintended to aid in the rapid differentialdiagnosis of Influenza A and B viralinfections. Negative test results shouldbe confirmed by cell culture.</td></tr><tr><td colspan="1" rowspan="1">Qualitative/Quantitative</td><td colspan="1" rowspan="1">Qualitative</td><td colspan="1" rowspan="1">Qualitative</td></tr><tr><td colspan="1" rowspan="1">Test Principle</td><td colspan="1" rowspan="1">Immunochromatographic fluorescenceimmunoassay</td><td colspan="1" rowspan="1">Immunochromatographic colloidal goldimmunoassay</td></tr><tr><td colspan="1" rowspan="1">Antibodies Used</td><td colspan="1" rowspan="1">Two mouse monoclonal antibodiesrecognizing the nucleoprotein of theInfluenza A virus and two mousemonoclonal antibodies recognizing thenucleoprotein of the Influenza B virus.</td><td colspan="1" rowspan="1">Unknown antibodies recognizing thenucleoprotein of the Influenza A andinfluenza B viruses.</td></tr><tr><td colspan="1" rowspan="1">Specimen Type</td><td colspan="1" rowspan="1">Nasal wash, nasal aspirate,nasopharyngeal aspirate, andnasopharyngeal swab specimens</td><td colspan="1" rowspan="1">Nasal wash, nasal swab,nasopharyngeal aspirate, andnasopharyngeal swab specimens</td></tr><tr><td colspan="1" rowspan="1">Reagent Stability</td><td colspan="1" rowspan="1">In sealed pouch: Up to stated expirationdate stored at 15-30°C. Do not removefrom pouch until ready to use.</td><td colspan="1" rowspan="1">In sealed pouch: Up to stated expirationdate stored at 15-30°C. Do not removefrom pouch until ready to use.</td></tr><tr><td colspan="1" rowspan="1">Test Time</td><td colspan="1" rowspan="1">15 minutes</td><td colspan="1" rowspan="1">15 minutes</td></tr><tr><td colspan="1" rowspan="1">Waste Handling</td><td colspan="1" rowspan="1">Dispose of Test Cartridge as per correctinstitutional biohazard procedure.</td><td colspan="1" rowspan="1">Dispose of Test Cartridge as per correctinstitutional biohazard procedure.</td></tr><tr><td colspan="1" rowspan="1">Self Contained</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Portable</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Patient Usage</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Standard Curve</td><td colspan="1" rowspan="1">Not Applicable</td><td colspan="1" rowspan="1">Not Applicable</td></tr><tr><td colspan="1" rowspan="1">External Controls</td><td colspan="1" rowspan="1">RAMP Influenza A/B Test kit containsPositive and Negative Control swabs.These swabs will monitor theperformance of the entire system.</td><td colspan="1" rowspan="1">BinaxNOW Influenza A&amp;B Test kitcontains Positive and Negative Controlswabs. These swabs will monitor theperformance of the entire assay.</td></tr><tr><td colspan="1" rowspan="1">Analytes</td><td colspan="1" rowspan="1">Influenza A and Influenza B</td><td colspan="1" rowspan="1">Influenza A and Influenza B</td></tr><tr><td colspan="1" rowspan="1">Product Type</td><td colspan="1" rowspan="1">In Vitro Diagnostic</td><td colspan="1" rowspan="1">In Vitro Diagnostic</td></tr></table>

<table><tr><td colspan="3" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">RAMP Influenza A/B Assay</td><td colspan="1" rowspan="1">BinaxNOW Influenza A &amp; BTest</td></tr><tr><td colspan="1" rowspan="1">Features/TechnicalInformation</td><td colspan="2" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Sample Preparation</td><td colspan="1" rowspan="1">Use provided disposable dropper tomix the sample in provided pre-measured sample buffer vial.</td><td colspan="1" rowspan="1">Elution of swab in sample buffer. Nonefor aspirate.</td></tr><tr><td colspan="1" rowspan="1">Test Procedure</td><td colspan="1" rowspan="1">Mix sample with provided transferdevice and add sample to TestCartridge.</td><td colspan="1" rowspan="1">Add sample to Test Device in a drop-wise manner expelling all materialfrom the Binax supplied pipette.</td></tr><tr><td colspan="1" rowspan="1">Automated Processing</td><td colspan="1" rowspan="1">Instrument transport of TestCartridge within reader is the onlymoving step. No internal liquidhandling. One-stepimmunochromatographic assayrequiring no additional washes.</td><td colspan="1" rowspan="1">Added sample develops on Test Deviceproviding visual result.</td></tr><tr><td colspan="1" rowspan="1">Read Results</td><td colspan="1" rowspan="1">Read results on instrument screen,or print with optional printer.</td><td colspan="1" rowspan="1">Visual read for presence or absence ofcontrol and test lines.</td></tr><tr><td colspan="1" rowspan="1">Instrument</td><td colspan="1" rowspan="1">RAMP 200</td><td colspan="1" rowspan="1">None</td></tr><tr><td colspan="1" rowspan="1">Automated Analysis</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">No. Operator must read result precisely15 minutes after sample application.Results read before or after 15 minutesmay not be accurate.</td></tr><tr><td colspan="1" rowspan="1">Quality Controls</td><td colspan="1" rowspan="1">Provided in every Test Cartridge.Built in performance controls forroutine QC requirements. Acomparison of the internalstandard and the assay resultindicates that sufficient properlymixed sample was appliedto the test device and that unboundfluorescent label washed sufficientlyfrom the detection zone, and thedevice was inserted and readproperly by the instrument.Background fluorescencemeasurement serves as a negativecontrol. Reader controls also preventa used or expired cartridge frombeing read by the reader. Antibodyquality, system function and assaytiming are checked on each assayrun. An unacceptable resultfrom the control displays a warningmessage without a test result on theinstrument indicating that the testshould be repeated.</td><td colspan="1" rowspan="1">Provided in every Test Device. Built-inprocedural controls. An untested devicehas a blue line at the "Control"position. If the test flows and thereagents work, this blue line willalways turn pink in a tested device. Theclearing of background color from theresult window is a negative backgroundcontrol. The background color in thewindow should be light pink to whitewithin 15 minutes. Background colorshould not hinder reading of the test.</td></tr><tr><td colspan="1" rowspan="1">System Quality Control</td><td colspan="1" rowspan="1">A built-in Internal Quality Control(IQC) function performs anautomated test of all Readeranalytical systems on a scheduled oroperator-determined basis to providea record of proper Readerfunctionality.</td><td colspan="1" rowspan="1">Not Applicable</td></tr><tr><td colspan="1" rowspan="1">Calibrator</td><td colspan="1" rowspan="1">Lot card contains calibration andexpiration information and issupplied with every kit.System will not process cartridge iflot card information is not stored ininstrument.</td><td colspan="1" rowspan="1">Not Applicable</td></tr><tr><td colspan="1" rowspan="1">Result Interpretation</td><td colspan="1" rowspan="1">Negative or Positive for Influenza Aand B; automated analysis, resultdisplayed on LCD screen ofinstrument</td><td colspan="1" rowspan="1">Negative or Positive for Influenza A orB; result visually read by presence orabsence of test lines at 15 minutesfollowing sample application.Results read before or after 15 minutesmay be inaccurate.</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

Not applicable.

# L. Test Principle:

The RAMP Influenza A/B Assay is a qualitative immunochromatographic test that utilizes the ${ \mathrm { R A M P } } ^ { \mathrm { \textregistered } }$ 200 reader for the differential determination of Influenza A and Influenza B in nasal wash/aspirate, nasopharyngeal aspirate, and nasopharyngeal swab samples. A wash/aspirate or swab sample is mixed with Sample Buffer using Assay Tip containing fluorescent-dyed latex particles coated with monoclonal antibodies targeting the Influenza A and B nucleoproteins, and applied into the sample well of the Test Cartridge. The sample migrates along the strip. Fluorescent-dyed latex (test) particles, coated with anti-Influenza A and anti-Influenza B nucleoprotein monoclonal antibodies bind to Influenza A or B nucleoprotein antigens, respectively, if present in the sample. As the sample migrates along the strip, Influenza-bound particles are captured at either the Influenza A or the Influenza B detection zone which is coated with either anti-Influenza A or anti-Influenza B nucleoprotein monoclonal antibodies, respectively. Excess fluorescent- dyed particles are captured at the internal standard zone. ${ \mathrm { R A M P } } ^ { \mathrm { \textregistered } }$ 200 reader then measures the amount of fluorescence emitted by the complexes bound at the two detection zones (Influenza A and Influenza B) and at the internal standard zone. The ${ \mathrm { R A M P } } ^ { \mathrm { \textregistered } }$ 200 reader calculates a ratio (RAMP Ratio) of each influenza zone (A or B) fluorescence reading to the internal standard zone fluorescence reading. The reader compares these ratios to pre-defined threshold limits to determine a positive or negative result for Influenza A and Influenza B in the tested sample.

The ${ \mathrm { R A M P } } ^ { \textcircled { \mathrm { \sc } } } 2 0 0$ is a general use fluorometer that analyzes results produced by immunoassays that use a fluorophore having an excitation wavelength of $5 6 0 \mathrm { n m }$ and an emission wavelength of $6 1 0 \mathrm { n m }$ .

![](images/a8e123103467dbbb2b5ff9360ab74b55ff263db69de08879e3a189da48640334.jpg)

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

The reproducibility of the RAMP Influenza A/B Assay was evaluated using a panel of 6 simulated samples that included high negative, low positive (the assay LoD) and moderate positive (2 X the assay LoD) Influenza A or Influenza B samples. The influenza strains used to prepare the simulated samples were Influenza A/Hong Kong/8/68 and Influenza B/Lee/40. The influenza strains were re-titered prior to testing. Panel samples were tested in triplicates at each of the 3 testing sites by 2 operators for 5 days using 1 RAMP Influenza $\mathrm { A } / \mathrm { B }$ kit lot (6 samples X 3 replicates X 2 operators X 5 days $\textrm { X } 3$ sites $= 5 4 0$ ). The overall percent agreement for the RAMP Influenza $\mathrm { A } / \mathrm { B }$ Assay was $100 \%$ , with no significant differences within run (same operator on same day), between run, operators, and sites. The RAMP Flu $\mathrm { A } / \mathrm { B }$ assay is a qualitative assay based on numerical RAMP Ratio values. The overall RAMP Ratio $\% \mathrm { C V }$ across all sites ranged from $9 . 6 \%$ to $1 5 . 1 \%$ depending upon analyte type and concentration tested.

<table><tr><td colspan="1" rowspan="2"></td><td colspan="1" rowspan="1">PanelMemberID</td><td colspan="1" rowspan="1">Influenza AHighNegative</td><td colspan="1" rowspan="1">Influenza ALowPositive</td><td colspan="1" rowspan="1">Influenza AMediumPositive</td><td colspan="1" rowspan="1">Influenza BHighNegative</td><td colspan="1" rowspan="1">Influenza BLowPositive</td><td colspan="1" rowspan="1">Influenza BMediumPositive</td><td colspan="1" rowspan="2">TotalAgreementAll (%)</td></tr><tr><td colspan="1" rowspan="1">Viral Titer(EID50/ml)</td><td colspan="1" rowspan="1">50</td><td colspan="1" rowspan="1">300</td><td colspan="1" rowspan="1">600</td><td colspan="1" rowspan="1">60</td><td colspan="1" rowspan="1">316</td><td colspan="1" rowspan="1">632</td></tr><tr><td colspan="1" rowspan="3">Site 1</td><td colspan="1" rowspan="1">AgreementwithExpectedresult</td><td colspan="1" rowspan="1">30/30</td><td colspan="1" rowspan="1">30/30</td><td colspan="1" rowspan="1">30/30</td><td colspan="1" rowspan="1">30/30</td><td colspan="1" rowspan="1">30/30</td><td colspan="1" rowspan="1">30/30</td><td colspan="1" rowspan="3">180/180 (100%)</td></tr><tr><td colspan="1" rowspan="1">MeanRAMPRatioValue</td><td colspan="1" rowspan="1">692</td><td colspan="1" rowspan="1">2224</td><td colspan="1" rowspan="1">4252</td><td colspan="1" rowspan="1">414</td><td colspan="1" rowspan="1">1192</td><td colspan="1" rowspan="1">2045</td></tr><tr><td colspan="1" rowspan="1">% CV</td><td colspan="1" rowspan="1">11.6%</td><td colspan="1" rowspan="1">6.3%</td><td colspan="1" rowspan="1">7.9%</td><td colspan="1" rowspan="1">16.4%</td><td colspan="1" rowspan="1">8.9%</td><td colspan="1" rowspan="1">7.9%</td></tr><tr><td colspan="1" rowspan="3">Site 2</td><td colspan="1" rowspan="1">AgreementwithExpectedresult</td><td colspan="1" rowspan="1">30/30</td><td colspan="1" rowspan="1">30/30</td><td colspan="1" rowspan="1">30/30</td><td colspan="1" rowspan="1">30/30</td><td colspan="1" rowspan="1">30/30</td><td colspan="1" rowspan="1">30/30</td><td colspan="1" rowspan="3">180/180 (100%)</td></tr><tr><td colspan="1" rowspan="1">MeanRAMPRatioValue</td><td colspan="1" rowspan="1">661</td><td colspan="1" rowspan="1">1993</td><td colspan="1" rowspan="1">3859</td><td colspan="1" rowspan="1">384</td><td colspan="1" rowspan="1">1076</td><td colspan="1" rowspan="1">1952</td></tr><tr><td colspan="1" rowspan="1">% CV</td><td colspan="1" rowspan="1">7.7%</td><td colspan="1" rowspan="1">8.1%</td><td colspan="1" rowspan="1">9.3%</td><td colspan="1" rowspan="1">15.6%</td><td colspan="1" rowspan="1">9.5%</td><td colspan="1" rowspan="1">7.0%</td></tr><tr><td colspan="1" rowspan="3">Site 3</td><td colspan="1" rowspan="1">AgreementwithExpectedresult</td><td colspan="1" rowspan="1">30/30</td><td colspan="1" rowspan="1">30/30</td><td colspan="1" rowspan="1">30/30</td><td colspan="1" rowspan="1">30/30</td><td colspan="1" rowspan="1">30/30</td><td colspan="1" rowspan="1">30/30</td><td colspan="1" rowspan="3">180/180 (100%)</td></tr><tr><td colspan="1" rowspan="1">MeanRAMPRatioValue</td><td colspan="1" rowspan="1">704</td><td colspan="1" rowspan="1">2326</td><td colspan="1" rowspan="1">4545</td><td colspan="1" rowspan="1">431</td><td colspan="1" rowspan="1">1212</td><td colspan="1" rowspan="1">2164</td></tr><tr><td colspan="1" rowspan="1">% CV</td><td colspan="1" rowspan="1">14.5%</td><td colspan="1" rowspan="1">9.9%</td><td colspan="1" rowspan="1">13.5%</td><td colspan="1" rowspan="1">11.3%</td><td colspan="1" rowspan="1">9.5%</td><td colspan="1" rowspan="1">10.5%</td></tr><tr><td colspan="1" rowspan="4"></td><td colspan="1" rowspan="1">TotalAgreementwithExpectedresult</td><td colspan="1" rowspan="1">90/90(100%)</td><td colspan="1" rowspan="1">90/90(100%)</td><td colspan="1" rowspan="1">90/90(100%)</td><td colspan="1" rowspan="1">90/90(100%)</td><td colspan="1" rowspan="1">90/90(100%)</td><td colspan="1" rowspan="1">90/90(100%)</td><td colspan="1" rowspan="1">540/540(100%)</td></tr><tr><td colspan="1" rowspan="1">95% CI</td><td colspan="1" rowspan="1">96%-100%</td><td colspan="1" rowspan="1">96%-100%</td><td colspan="1" rowspan="1">96%-100%</td><td colspan="1" rowspan="1">96%-100%</td><td colspan="1" rowspan="1">96%-100%</td><td colspan="1" rowspan="1">96%-100%</td><td colspan="1" rowspan="1">99%-100%</td></tr><tr><td colspan="1" rowspan="1">OverallMeanRAMPRatio</td><td colspan="1" rowspan="1">685</td><td colspan="1" rowspan="1">2181</td><td colspan="1" rowspan="1">4219</td><td colspan="1" rowspan="1">410</td><td colspan="1" rowspan="1">1160</td><td colspan="1" rowspan="1">2054</td><td colspan="1" rowspan="2"></td></tr><tr><td colspan="1" rowspan="1">Overall% CV</td><td colspan="1" rowspan="1">11.9%</td><td colspan="1" rowspan="1">10.4%</td><td colspan="1" rowspan="1">12.6%</td><td colspan="1" rowspan="1">15.1%</td><td colspan="1" rowspan="1">10.6%</td><td colspan="1" rowspan="1">9.6%</td></tr></table>

$b$ . Linearity/assay reportable range: Not applicable.   
c. Traceability, Stability, Expected values (controls, calibrators, or methods): Not applicable.

d. Detection limit:

The analytical sensitivity (limit of detection or LoD) of the RAMP Influenza A/B Assay was determined using quantified $\mathrm { ( E I D _ { 5 0 } / m L ) }$ ) cultures of 2 Influenza A (1 H1N1 and 1 H3N2) and 2 Influenza B strains serially diluted in either viral transfer media (VTM) to simulate a swab sample type or phosphate buffered saline (PBS) solution to simulate a wash/aspirate sample type. The influenza strains were re-titered prior to testing. Each viral strain was tested in replicates of 20 per concentration of virus.

Analytical sensitivity (LoD) as defined as the lowest concentration, at which $\geq$ $9 5 \%$ of all replicates tested positive, ranged from $3 . 0 \mathrm { x } 1 0 ^ { 2 }$ to $6 . 4 \mathrm { x } 1 0 ^ { 2 } \mathrm { E I D } 5 0 / \mathrm { m L }$ for the Influenza A strains and $\dot { 2 } . 8 \mathrm { x } 1 0 ^ { 2 }$ to $7 . 1 \mathrm { { x } 1 0 ^ { 4 } E I D 5 0 / m L }$ for the Influenza B strains in VTM and PBS.

<table><tr><td colspan="1" rowspan="1">Viral Strain</td><td colspan="1" rowspan="1">LoD Concentration</td></tr><tr><td colspan="1" rowspan="1">Influenza A/Hong Kong/8/68 (H3N2),ATCC VR-544 in VTM</td><td colspan="1" rowspan="1">3.0 X 102 EID50/ml</td></tr><tr><td colspan="1" rowspan="1">Influenza A/Hong Kong/8/68 (H3N2),ATCC VR-544 in PBS</td><td colspan="1" rowspan="1">5.0 X 102 EID50/ml</td></tr><tr><td colspan="1" rowspan="1">Influenza A/PR/8/34 (H1N1),ATCC VR-95 in VTM</td><td colspan="1" rowspan="1">2.0 X 102 EID50/ml</td></tr><tr><td colspan="1" rowspan="1">Influenza A/PR/8/34 (H1N1),ATCC VR-95 in PBS</td><td colspan="1" rowspan="1">6.4 X 102 EID50/ml</td></tr><tr><td colspan="1" rowspan="1">Influenza B/Lee/40,ATCC VR-101 in VTM</td><td colspan="1" rowspan="1">3.2 X 102 EID50/ml</td></tr><tr><td colspan="1" rowspan="1">Influenza B/Lee/40,ATCC VR-101 in PBS</td><td colspan="1" rowspan="1">2.8 X 102 EID50/ml</td></tr><tr><td colspan="1" rowspan="1">Influenza B/Allen/45,ATCC VR-102 in VTM</td><td colspan="1" rowspan="1">5.3 X 104 EID50/ml</td></tr><tr><td colspan="1" rowspan="1">Influenza B/Allen/45,ATCC VR-102 in PBS</td><td colspan="1" rowspan="1">7.1 X 104 EID50/ml</td></tr></table>

# e. Analytical reactivity:

The analytical reactivity of the RAMP Influenza A/B Assay was evaluated against multiple strains of Influenza A (H1N1 and H3N2 subtypes) and Influenza B. The panel consisted of 3 Influenza A subtype H1N1, 2 Influenza A subtype H3N2, and 3 Influenza B strains. 5 replicates were tested for each viral strain. The concentrations for analytical reactivity testing ranged from $3 . 0 \mathrm { x } 1 0 ^ { 2 }$ to $3 . 0 \mathrm { x } 1 0 ^ { 3 }$ $\mathrm { E I D } 5 0 / \mathrm { m L }$ for the Influenza A strains and $1 . 6 \mathrm { \bar { x } } 1 0 ^ { 1 }$ to $9 . 5 \mathrm { x } 1 0 ^ { 3 } \mathrm { E I D } 5 0 / \mathrm { m L }$ for the Influenza B strains. The influenza strains were re-titered prior to testing.

<table><tr><td rowspan=1 colspan=1>Viral Strain</td><td rowspan=1 colspan=1>Analytical ReactivityConcentration</td><td rowspan=1 colspan=1>RAMP Assay Result</td></tr><tr><td rowspan=1 colspan=1>Influenza A/FM/1/47 (H1N1)ATCC VR-97</td><td rowspan=1 colspan=1>3.0 X 103 EID50/ml</td><td rowspan=1 colspan=1>5/5 Flu A Positive</td></tr><tr><td rowspan=1 colspan=1>Influenza A/NWS/33 (H1N1)ATCC VR-219</td><td rowspan=1 colspan=1>3.0 X 102 EID50/ml</td><td rowspan=1 colspan=1>5/5 Flu A Positive</td></tr><tr><td rowspan=1 colspan=1>Influenza A/New Jersey/8/76(H1N1), ATCC VR-897</td><td rowspan=1 colspan=1>3.0 X 102 EID50/ml</td><td rowspan=1 colspan=1>5/5 Flu A Positive</td></tr><tr><td rowspan=1 colspan=1>Influenza A/Aichi/2/68(H3N2)ATCC VR-547</td><td rowspan=1 colspan=1>9.0 X 102 EID50/ml</td><td rowspan=1 colspan=1>5/5 Flu A Positive</td></tr><tr><td rowspan=1 colspan=1>Influenza A/Victoria/3/75(H3N2), ATCC VR-822</td><td rowspan=1 colspan=1>9.0 X 102 EID50/ml</td><td rowspan=1 colspan=1>5/5 Flu A Positive</td></tr><tr><td rowspan=1 colspan=1>Influenza B/GL/1739/54ATCC VR-103</td><td rowspan=1 colspan=1>9.5 X 103 EID50/ml</td><td rowspan=1 colspan=1>5/5 Flu B Positive</td></tr><tr><td rowspan=1 colspan=1>Influenza B/Taiwan/2/62ATCC VR-295</td><td rowspan=1 colspan=1>1.6 X 101 EID50/ml</td><td rowspan=1 colspan=1>5/5 Flu B Positive</td></tr><tr><td rowspan=1 colspan=1>Influenza B/Hong Kong/5/72ATCC VR-823</td><td rowspan=1 colspan=1>6.3 X 103 EID50/ml</td><td rowspan=1 colspan=1>5/5 Flu B Positive</td></tr></table>

f. Analytical specificity:

The analytical specificity of the RAMP Influenza $\mathrm { A } / \mathrm { B }$ Assay was evaluated by testing a panel consisting of 17 bacteria and 15 viruses that may be present in the nasal cavity or nasopharynx. Bacterial isolates were tested at $\mathrm { 1 0 ^ { 6 } c f u / m L }$ and viral isolates were tested at approximately $1 0 ^ { 5 } \mathrm { T C I D 5 0 / m L }$ at $\mathrm { n } { = } 3$ replicates each. The bacterial and viral organisms were re-grown and re-titered prior to cross-reactivity testing. Analytical specificity of the RAMP Influenza $\mathrm { A } / \mathrm { B }$ Assay was $100 \%$ .

<table><tr><td rowspan=1 colspan=1>Strain/Isolate</td><td rowspan=1 colspan=1>Concentration</td><td rowspan=1 colspan=1>RAMP FluA result</td><td rowspan=1 colspan=1>RAMP FluB result</td></tr><tr><td rowspan=1 colspan=1>Adenovirus, Type 1</td><td rowspan=1 colspan=1>105 TCID50/mL</td><td rowspan=1 colspan=1>3/3 Neg</td><td rowspan=1 colspan=1>3/3 Neg</td></tr><tr><td rowspan=1 colspan=1>Adenovirus, Type 7a</td><td rowspan=1 colspan=1>105.15 TCID50/mL</td><td rowspan=1 colspan=1>3/3 Neg</td><td rowspan=1 colspan=1>3/3 Neg</td></tr><tr><td rowspan=1 colspan=1>Respiratory Syncytial Virus (RSV)</td><td rowspan=1 colspan=1>105 TCID50/mL</td><td rowspan=1 colspan=1>3/3 Neg</td><td rowspan=1 colspan=1>3/3 Neg</td></tr><tr><td rowspan=1 colspan=1>Human coronavirus, strain OC43</td><td rowspan=1 colspan=1>105 TCID50/mL</td><td rowspan=1 colspan=1>3/3 Neg</td><td rowspan=1 colspan=1>3/3 Neg</td></tr><tr><td rowspan=1 colspan=1>Human coronavirus Strain 229E</td><td rowspan=1 colspan=1>105.23TCID50/mL</td><td rowspan=1 colspan=1>3/3 Neg</td><td rowspan=1 colspan=1>3/3 Neg</td></tr><tr><td rowspan=1 colspan=1>Cytomegalovirus</td><td rowspan=1 colspan=1>105.15 TCID50/mL</td><td rowspan=1 colspan=1>3/3 Neg</td><td rowspan=1 colspan=1>3/3 Neg</td></tr><tr><td rowspan=1 colspan=1>Enterovirus, Type 68</td><td rowspan=1 colspan=1>105.15 TCID50/mL</td><td rowspan=1 colspan=1>3/3 Neg</td><td rowspan=1 colspan=1>3/3 Neg</td></tr><tr><td rowspan=1 colspan=1>Epstein Barr Virus</td><td rowspan=1 colspan=1>105 TCID50/mL</td><td rowspan=1 colspan=1>3/3 Neg</td><td rowspan=1 colspan=1>3/3 Neg</td></tr><tr><td rowspan=1 colspan=1>Measles</td><td rowspan=1 colspan=1>105 TCID50/mL</td><td rowspan=1 colspan=1>3/3 Neg</td><td rowspan=1 colspan=1>3/3 Neg</td></tr><tr><td rowspan=1 colspan=1>Mumps virus</td><td rowspan=1 colspan=1>105 TCID50/mL</td><td rowspan=1 colspan=1>3/3 Neg</td><td rowspan=1 colspan=1>3/3 Neg</td></tr><tr><td rowspan=1 colspan=1>Human Parainfluenza, Type 1</td><td rowspan=1 colspan=1>104.75 TCID50/mL</td><td rowspan=1 colspan=1>3/3 Neg</td><td rowspan=1 colspan=1>3/3 Neg</td></tr><tr><td rowspan=1 colspan=1>Human Parainfluenza, Type 2</td><td rowspan=1 colspan=1>105 TCID50/mL</td><td rowspan=1 colspan=1>3/3 Neg</td><td rowspan=1 colspan=1>3/3 Neg</td></tr><tr><td rowspan=1 colspan=1>Human Parainfluenza, Type 3</td><td rowspan=1 colspan=1>105 TCID50/mL</td><td rowspan=1 colspan=1>3/3 Neg</td><td rowspan=1 colspan=1>3/3 Neg</td></tr><tr><td rowspan=1 colspan=1>Human metapneumovirus</td><td rowspan=1 colspan=1>105 TCID50/mL</td><td rowspan=1 colspan=1>3/3 Neg</td><td rowspan=1 colspan=1>3/3 Neg</td></tr><tr><td rowspan=1 colspan=1>Human Rhinovirus, Strain 1A</td><td rowspan=1 colspan=1>105 TCID50/mL</td><td rowspan=1 colspan=1>3/3 Neg</td><td rowspan=1 colspan=1>3/3 Neg</td></tr><tr><td rowspan=1 colspan=1>Bordetella pertussis</td><td rowspan=1 colspan=1>106 cfu/mL</td><td rowspan=1 colspan=1>3/3 Neg</td><td rowspan=1 colspan=1>3/3 Neg</td></tr><tr><td rowspan=1 colspan=1>Corynebacterium Sp.</td><td rowspan=1 colspan=1>106 cfu/mL</td><td rowspan=1 colspan=1>3/3 Neg</td><td rowspan=1 colspan=1>3/3 Neg</td></tr><tr><td rowspan=1 colspan=1>Escherichia coli</td><td rowspan=1 colspan=1>106 cfu/mL</td><td rowspan=1 colspan=1>3/3 Neg</td><td rowspan=1 colspan=1>3/3 Neg</td></tr><tr><td rowspan=1 colspan=1>Haemophilus influenzae</td><td rowspan=1 colspan=1>106 cfu/mL</td><td rowspan=1 colspan=1>3/3 Neg</td><td rowspan=1 colspan=1>3/3 Neg</td></tr><tr><td rowspan=1 colspan=1>Lactobacillus casei</td><td rowspan=1 colspan=1>106 cfu/mL</td><td rowspan=1 colspan=1>3/3 Neg</td><td rowspan=1 colspan=1>3/3 Neg</td></tr><tr><td rowspan=1 colspan=1>Legionella pneumophila</td><td rowspan=1 colspan=1>106 cfu/mL</td><td rowspan=1 colspan=1>3/3 Neg</td><td rowspan=1 colspan=1>3/3 Neg</td></tr><tr><td rowspan=1 colspan=1>Moraxella catarrhalis</td><td rowspan=1 colspan=1>106 cfu/mL</td><td rowspan=1 colspan=1>3/3 Neg</td><td rowspan=1 colspan=1>3/3 Neg</td></tr><tr><td rowspan=1 colspan=1>Mycobacterium tuberculosis avirulent</td><td rowspan=1 colspan=1>106 cfu/mL</td><td rowspan=1 colspan=1>3/3 Neg</td><td rowspan=1 colspan=1>3/3 Neg</td></tr><tr><td rowspan=1 colspan=1>Mycoplasma pneumoniae</td><td rowspan=1 colspan=1>106 cfu/mL</td><td rowspan=1 colspan=1>3/3 Neg</td><td rowspan=1 colspan=1>3/3 Neg</td></tr><tr><td rowspan=1 colspan=1>Neisseria menigitidis</td><td rowspan=1 colspan=1>106 cfu/mL</td><td rowspan=1 colspan=1>3/3 Neg</td><td rowspan=1 colspan=1>3/3 Neg</td></tr><tr><td rowspan=1 colspan=1>Neisseria sicca</td><td rowspan=1 colspan=1>106 cfu/mL</td><td rowspan=1 colspan=1>3/3 Neg</td><td rowspan=1 colspan=1>3/3 Neg</td></tr><tr><td rowspan=1 colspan=1>Psudomonas aeruginosa</td><td rowspan=1 colspan=1>106 cfu/mL</td><td rowspan=1 colspan=1>3/3 Neg</td><td rowspan=1 colspan=1>3/3 Neg</td></tr><tr><td rowspan=1 colspan=1>Streptococcus pneumoniae</td><td rowspan=1 colspan=1>106 cfu/mL</td><td rowspan=1 colspan=1>3/3 Neg</td><td rowspan=1 colspan=1>3/3 Neg</td></tr><tr><td rowspan=1 colspan=1>Streptococcus pyogenes (Group A)</td><td rowspan=1 colspan=1>106 cfu/mL</td><td rowspan=1 colspan=1>3/3 Neg</td><td rowspan=1 colspan=1>3/3 Neg</td></tr><tr><td rowspan=1 colspan=1>Streptococcus salivarius</td><td rowspan=1 colspan=1>106 cfu/mL</td><td rowspan=1 colspan=1>3/3 Neg</td><td rowspan=1 colspan=1>3/3 Neg</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus epidermidis</td><td rowspan=1 colspan=1>106 cfu/mL</td><td rowspan=1 colspan=1>3/3 Neg</td><td rowspan=1 colspan=1>3/3 Neg</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus aureus (Protein Aproducer)</td><td rowspan=1 colspan=1>106 cfu/mL</td><td rowspan=1 colspan=1>3/3 Neg</td><td rowspan=1 colspan=1>3/3 Neg</td></tr></table>

Note: RAMP Influenza A/B Assay potential cross-reactivity with Chlamydophilia pneumoniae has not been determined.

The lot-specific Threshold 1 (Normal cut-off) values and the fixed Threshold 2 (Extreme cut-off) values are programmed into the lot-specific Lot Cards and thus the RAMP Ratio values are invisible to the end user. Only negative or positive results are displayed. The Lot Card provides the reader with information specific to the lot, including lot number, expiration date, thresholds and standard curve information.

A. Threshold 1 (Normal cut-off):

1) Each RAMP Influenza A/B kit has lot-specific Threshold 1 levels. The Threshold 1 values (separate values for Influenza A and Influenza B) for each lot are based on QC testing data of the specific combination of component lots (Sample Buffer, Test Cartridge, and Assay Tips) used in the Influenza A/B kit lot. QC testing is performed on each kit lot to ensure that the lot meets release specifications as well as to provide the data to set the Threshold 1 values.

The algorithm used to determine the lot-specific Threshold 1 values is the same for each lot and uses defined calculations based on the results of the QC testing data of that lot, and the Threshold Factors that were based on the clinical trial results to optimize sensitivity and specificity of the RAMP Influenza A/B test (ROC Optimization).

B. Threshold 2 (Extreme cut-off):

1) During development of the RAMP Influenza A/B Assay, it was observed that when testing clinical samples with extremely high concentrations of Influenza A, there appeared to be interference in the Influenza B Assay potentially resulting in a False Positive Influenza B result in addition to the true positive Influenza A result. Testing was performed on the four Influenza A/B kit lots manufactured for the clinical trials to characterize this interference between multiple lots of the Influenza A/B Assays. Based on this testing, it was observed that the interference was very reproducible between kit lots. Threshold 2 values of 20,000 for Influenza A and 10,000 were arbitrarily set. The pre-determined "extreme" Threshold 2 values are fixed values and are applied to all test kit lots.

2) Based on this characterization of the interference of high levels of Influenza A antigen in the Influenza B Assay, an algorithm was derived to provide Threshold 1 for clinical samples that are negative or have low to moderate levels of Influenza A, but to switch to Threshold 2 if a double positive (Influenza A and Influenza B) was determined and the level of Influenza A was extremely high.

Because a simultaneous double infection of Influenza A and Influenza B in the same patient is exceedingly rare, the algorithm and Threshold 2 values were biased towards minimizing the possibility of displaying a double Influenza A positive and Influenza B positive result.

# h. Interfering Substances:

Whole blood and a number of other potentially interfering substances (medications and over the counter (OTC) products) that may be present naturally or artificially introduced in the nasal cavity or nasopharynx were evaluated in the RAMP Influenza A/B Assay. The substances were added to a negative sample (viral transport media), an Influenza A LoD positive sample (300 $\mathrm { E I D 5 0 / m L }$ ), an Influenza A 2x LoD positive sample $( 6 0 0 \mathrm { E I D 5 0 / m L } )$ ), an Influenza B LoD positive sample $( 3 1 6 ~ \mathrm { E I D 5 0 / m L } )$ and an Influenza B $2 \mathbf { x }$ LoD positive sample $( 6 3 2 \mathrm { E I D } 5 0 / \mathrm { m L } )$ and tested at $\mathrm { n } { = } 3$ replicates each in the RAMP Influenza A/B Assay. The influenza strains used to prepare the samples were Influenza A/Hong Kong/8/68 and Influenza B/Lee/40. These influenza strains were re-titered prior to interference testing.

None of the substances tested at the concentrations indicated interfere with the test results of negative or positive Influenza A and Influenza B samples in the RAMP Influenza A/B Assay. The RAMP Flu A/B assay is a qualitative assay based on numerical RAMP Ratio values. The Percent of Mean Control Ratio values were calculated using these RAMP Ratios.

<table><tr><td colspan="1" rowspan="2">Substance Tested</td><td colspan="1" rowspan="2">Conc.Tested</td><td colspan="10" rowspan="1">RAMP Results</td></tr><tr><td colspan="2" rowspan="1">Negative</td><td colspan="2" rowspan="1">Influenza A LoD</td><td colspan="2" rowspan="1">Influenza A 2x LoD</td><td colspan="2" rowspan="1">Influenza B LoD</td><td colspan="2" rowspan="1">Influenza B 2x LoD</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">RAMP FluA/B results</td><td colspan="1" rowspan="1">Percent ofMeanControlRatioFluA/FluB</td><td colspan="1" rowspan="1">RAMP FluA/B results</td><td colspan="1" rowspan="1">Percent ofMeanControlRatio</td><td colspan="1" rowspan="1">RAMP FluA/B results</td><td colspan="1" rowspan="1">Percent ofMeanControlRatio</td><td colspan="1" rowspan="1">RAMP FluA/B results</td><td colspan="1" rowspan="1">Percent ofMeanControlRatio</td><td colspan="1" rowspan="1">RAMP FluA/B results</td><td colspan="1" rowspan="1">Percent ofMeanControlRatio</td></tr><tr><td colspan="1" rowspan="1">Control(No interferingsubstance)</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">3/3 Neg</td><td colspan="1" rowspan="1">100%/100%</td><td colspan="1" rowspan="1">3/3 Flu A Pos</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">3/3 Flu APoss</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">100%</td></tr><tr><td colspan="1" rowspan="1">Halls ThroatDrop</td><td colspan="1" rowspan="1">15% w/v</td><td colspan="1" rowspan="1">3/3 Neg</td><td colspan="1" rowspan="1">120% /105%</td><td colspan="1" rowspan="1">3/3 Flu A Pos</td><td colspan="1" rowspan="1">101%</td><td colspan="1" rowspan="1">3/3 Flu APos</td><td colspan="1" rowspan="1">103%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">99%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">120%</td></tr><tr><td colspan="1" rowspan="1">Cepacol ThroatDrop</td><td colspan="1" rowspan="1">15% w/v</td><td colspan="1" rowspan="1">3/3 Neg</td><td colspan="1" rowspan="1">91%/101%</td><td colspan="1" rowspan="1">3/3 Flu A Pos</td><td colspan="1" rowspan="1">98%</td><td colspan="1" rowspan="1">3/3 Flu APos</td><td colspan="1" rowspan="1">101%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">105%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">118%</td></tr><tr><td colspan="1" rowspan="1">Fisherman'sFriend ThroatDrop</td><td colspan="1" rowspan="1">15% w/v</td><td colspan="1" rowspan="1">3/3 Neg</td><td colspan="1" rowspan="1">120% /105%</td><td colspan="1" rowspan="1">3/3 Flu A Pos</td><td colspan="1" rowspan="1">101%</td><td colspan="1" rowspan="1">3/3 Flu APos</td><td colspan="1" rowspan="1">103%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">99%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">120%</td></tr><tr><td colspan="1" rowspan="1">4-Acetamidophenol</td><td colspan="1" rowspan="1">10 mg/mL</td><td colspan="1" rowspan="1">3/3 Neg</td><td colspan="1" rowspan="1">110% /117%</td><td colspan="1" rowspan="1">3/3 Flu A Pos</td><td colspan="1" rowspan="1">99%</td><td colspan="1" rowspan="1">3/3 Flu APos</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">104%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">117%</td></tr><tr><td colspan="1" rowspan="1">AcetylsalicylicAcid</td><td colspan="1" rowspan="1">15 mg/mL</td><td colspan="1" rowspan="1">3/3 Neg</td><td colspan="1" rowspan="1">89%/106%</td><td colspan="1" rowspan="1">3/3 Flu A Pos</td><td colspan="1" rowspan="1">98%</td><td colspan="1" rowspan="1">3/3 Flu APos</td><td colspan="1" rowspan="1">97%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">110%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">118%</td></tr><tr><td colspan="1" rowspan="1">Chlorphiramine</td><td colspan="1" rowspan="1">5 mg/mL</td><td colspan="1" rowspan="1">3/3 Neg</td><td colspan="1" rowspan="1">107% /110%</td><td colspan="1" rowspan="1">3/3 Flu A Pos</td><td colspan="1" rowspan="1">101%</td><td colspan="1" rowspan="1">3/3 Flu APos</td><td colspan="1" rowspan="1">95%</td><td colspan="1" rowspan="1">3/3 Flu BPs</td><td colspan="1" rowspan="1">112%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">118%</td></tr><tr><td colspan="1" rowspan="1">Diphenylhydramine</td><td colspan="1" rowspan="1">5 mg/mL</td><td colspan="1" rowspan="1">3/3 Neg</td><td colspan="1" rowspan="1">109% /126%</td><td colspan="1" rowspan="1">3/3 Flu A Pos</td><td colspan="1" rowspan="1">99%</td><td colspan="1" rowspan="1">3/3 Flu APos</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">115%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">116%</td></tr><tr><td colspan="1" rowspan="1">Phenylpropanol-amine HCl</td><td colspan="1" rowspan="1">20 mg/mL</td><td colspan="1" rowspan="1">3/3 Neg</td><td colspan="1" rowspan="1">126%/100%</td><td colspan="1" rowspan="1">3/3 Flu A Pos</td><td colspan="1" rowspan="1">91%</td><td colspan="1" rowspan="1">3/3 Flu APos</td><td colspan="1" rowspan="1">96%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">113%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">113%</td></tr><tr><td colspan="1" rowspan="1">OseltamivirPhosphate(Tamiflu)</td><td colspan="1" rowspan="1">50 mg/mL</td><td colspan="1" rowspan="1">3/3 Neg</td><td colspan="1" rowspan="1">106% /101%</td><td colspan="1" rowspan="1">3/3 Flu A Pos</td><td colspan="1" rowspan="1">105%</td><td colspan="1" rowspan="1">3/3 Flu APos</td><td colspan="1" rowspan="1">105%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">106%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">111%</td></tr><tr><td colspan="1" rowspan="1">Rimantadine HCl</td><td colspan="1" rowspan="1">500 ng/mL</td><td colspan="1" rowspan="1">3/3 Neg</td><td colspan="1" rowspan="1">103% /103%</td><td colspan="1" rowspan="1">3/3 Flu A Pos</td><td colspan="1" rowspan="1">105%</td><td colspan="1" rowspan="1">3/3 Flu APos</td><td colspan="1" rowspan="1">94%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">111%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">113%</td></tr><tr><td colspan="1" rowspan="1">Ribavirin(Rebetol)</td><td colspan="1" rowspan="1">100mg/mL</td><td colspan="1" rowspan="1">3/3 Neg</td><td colspan="1" rowspan="1">137%/136%</td><td colspan="1" rowspan="1">3/3 Flu A Pos</td><td colspan="1" rowspan="1">111%</td><td colspan="1" rowspan="1">3/3 Flu APos</td><td colspan="1" rowspan="1">106%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">118%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">120%</td></tr><tr><td colspan="1" rowspan="1">ScopeMouthwash</td><td colspan="1" rowspan="1">20% v/v</td><td colspan="1" rowspan="1">3/3 Neg</td><td colspan="1" rowspan="1">88% / 99%</td><td colspan="1" rowspan="1">3/3 Flu A Pos</td><td colspan="1" rowspan="1">96%</td><td colspan="1" rowspan="1">3/3 Flu APos</td><td colspan="1" rowspan="1">94%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">98%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">112%</td></tr><tr><td colspan="1" rowspan="1">Good and KindMouthwash</td><td colspan="1" rowspan="1">20% v/v</td><td colspan="1" rowspan="1">3/3 Neg</td><td colspan="1" rowspan="1">97%/118%</td><td colspan="1" rowspan="1">3/3 Flu A Pos</td><td colspan="1" rowspan="1">97%</td><td colspan="1" rowspan="1">3/3 Flu APos</td><td colspan="1" rowspan="1">106%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">99%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">125%</td></tr><tr><td colspan="1" rowspan="1">Cepacol MouthWash</td><td colspan="1" rowspan="1">20% v/v</td><td colspan="1" rowspan="1">3/3 Neg</td><td colspan="1" rowspan="1">88% / 85%</td><td colspan="1" rowspan="1">3/3 Flu A Pos</td><td colspan="1" rowspan="1">103%</td><td colspan="1" rowspan="1">3/3 Flu APos</td><td colspan="1" rowspan="1">104%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">98%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">118%</td></tr><tr><td colspan="1" rowspan="1">Flonase NasalSpray</td><td colspan="1" rowspan="1">15% v/v</td><td colspan="1" rowspan="1">3/3 Neg</td><td colspan="1" rowspan="1">103% /104%</td><td colspan="1" rowspan="1">3/3 Flu A Pos</td><td colspan="1" rowspan="1">109%</td><td colspan="1" rowspan="1">3/3 Flu APos</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">95%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">113%</td></tr><tr><td colspan="1" rowspan="1">Rhinocort NasalSpray</td><td colspan="1" rowspan="1">15% v/v</td><td colspan="1" rowspan="1">3/3 Neg</td><td colspan="1" rowspan="1">85% / 88%</td><td colspan="1" rowspan="1">3/3 Flu A Pos</td><td colspan="1" rowspan="1">109%</td><td colspan="1" rowspan="1">3/3 Flu APos</td><td colspan="1" rowspan="1">101%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">90%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">122%</td></tr><tr><td colspan="1" rowspan="1">Nasonex NasalSpray</td><td colspan="1" rowspan="1">15% v/v</td><td colspan="1" rowspan="1">3/3 Neg</td><td colspan="1" rowspan="1">104% /90%</td><td colspan="1" rowspan="1">3/3 Flu A Pos</td><td colspan="1" rowspan="1">103%</td><td colspan="1" rowspan="1">3/3 Flu APos</td><td colspan="1" rowspan="1">106%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">92%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">113%</td></tr><tr><td colspan="1" rowspan="1">OxymetazolineHCl</td><td colspan="1" rowspan="1">0.05% v/v</td><td colspan="1" rowspan="1">3/3 Neg</td><td colspan="1" rowspan="1">116%/95%</td><td colspan="1" rowspan="1">3/3 Flu A Pos</td><td colspan="1" rowspan="1">101%</td><td colspan="1" rowspan="1">3/3 Flu APos</td><td colspan="1" rowspan="1">103%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">97%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">108%</td></tr><tr><td colspan="1" rowspan="1">PhenylephrineHCI</td><td colspan="1" rowspan="1">10 mg/mL</td><td colspan="1" rowspan="1">3/3 Neg</td><td colspan="1" rowspan="1">126% /119%</td><td colspan="1" rowspan="1">3/3 Flu A Pos</td><td colspan="1" rowspan="1">101%</td><td colspan="1" rowspan="1">3/3 Flu APos</td><td colspan="1" rowspan="1">99%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">106%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">117%</td></tr><tr><td colspan="1" rowspan="1">GuaiacolGlycerol Ether(Benylin)</td><td colspan="1" rowspan="1">20 mg/mL</td><td colspan="1" rowspan="1">3/3 Neg</td><td colspan="1" rowspan="1">166%/153%</td><td colspan="1" rowspan="1">3/3 Flu A Pos</td><td colspan="1" rowspan="1">118%</td><td colspan="1" rowspan="1">3/3 Flu APos</td><td colspan="1" rowspan="1">113%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">118%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">124%</td></tr><tr><td colspan="1" rowspan="1">Dextromethorphan</td><td colspan="1" rowspan="1">2 mg/mL</td><td colspan="1" rowspan="1">3/3 Neg</td><td colspan="1" rowspan="1">95%/101%</td><td colspan="1" rowspan="1">3/3 Flu A Pos</td><td colspan="1" rowspan="1">115%</td><td colspan="1" rowspan="1">3/3 Flu APos</td><td colspan="1" rowspan="1">115%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">126%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">134%</td></tr><tr><td colspan="1" rowspan="1">SalbutamolSulfate</td><td colspan="1" rowspan="1">400 ng/mL</td><td colspan="1" rowspan="1">3/3 Neg</td><td colspan="1" rowspan="1">102% /92%</td><td colspan="1" rowspan="1">3/3 Flu A Pos</td><td colspan="1" rowspan="1">98%</td><td colspan="1" rowspan="1">3/3 Flu APos</td><td colspan="1" rowspan="1">99%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">111%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">116%</td></tr><tr><td colspan="1" rowspan="1">Whole Blood*</td><td colspan="1" rowspan="1">2% v/v</td><td colspan="1" rowspan="1">3/3 Neg</td><td colspan="1" rowspan="1">126% /91%</td><td colspan="1" rowspan="1">3/3 Flu A Pos</td><td colspan="1" rowspan="1">75%</td><td colspan="1" rowspan="1">3/3 Flu APos</td><td colspan="1" rowspan="1">90%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">106%</td><td colspan="1" rowspan="1">3/3 Flu BPos</td><td colspan="1" rowspan="1">98%</td></tr></table>

\*A warning is added to the package insert to reflect that samples contaminated with whole blood in greater concentrations (visibly bloody samples) may interfere in the interpretation of the assay.

# i. Transport Media Compatibility:

Eight transport media (six commercial transport media and two clinical site prepared transport media) were evaluated for compatibility in the RAMP Influenza $\mathrm { A } / \mathrm { B }$ Assay by testing a negative sample (transport media only), an Influenza A LoD positive sample $( 3 0 0 ~ \mathrm { E I D } 5 0 / \mathrm { m L } )$ , an Influenza A 2x LoD positive sample $( 6 0 0 \mathrm { E I D 5 0 / m L } )$ , an Influenza B LoD positive sample (316 $\mathrm { E I D 5 0 / m l } )$ , and an Influenza B $2 \mathbf { x }$ LoD positive sample $( 6 3 2 \mathrm { E I D } 5 0 / \mathrm { m l } )$ at $\mathrm { n } { = } 3$ replicates each in the RAMP Influenza A/B Assay. The influenza strains used to prepare the samples were Influenza A/Hong Kong/8/68 and Influenza $\mathrm { B } / \mathrm { L e e } / 4 0$ . These influenza strains were re-titered prior to media testing. All negative samples (media only) tested negative. All inoculated samples (media with Influenza A or Influenza B) tested positive for the appropriate virus. The RAMP Flu $\mathrm { A } / \mathrm { B }$ assay is a qualitative assay based on numerical RAMP Ratio values. The $\% C V s$ were also calculated for the RAMP Ratios. None of the tested transport media interfered with the performance of the RAMP Influenza A/B Assay.

<table><tr><td rowspan=3 colspan=1>Transport MediaTested</td><td rowspan=1 colspan=10>RAMP Results</td></tr><tr><td rowspan=1 colspan=2>Negative</td><td rowspan=1 colspan=2>Influenza A LoD</td><td rowspan=1 colspan=2>Influenza A 2x LoD</td><td rowspan=1 colspan=2>Influenza B LoD</td><td rowspan=1 colspan=2>Influenza B 2x LoD</td></tr><tr><td rowspan=1 colspan=1>Results</td><td rowspan=1 colspan=1>MeanRAMPRatioFluA/FluB</td><td rowspan=1 colspan=1>Results</td><td rowspan=1 colspan=1>MeanRAMPRatio</td><td rowspan=1 colspan=1>Results</td><td rowspan=1 colspan=1>MeanRAMPRatio</td><td rowspan=1 colspan=1>Results</td><td rowspan=1 colspan=1>MeanRAMPRatio</td><td rowspan=1 colspan=1>Results</td><td rowspan=1 colspan=1>MeanRAMPRatio</td></tr><tr><td rowspan=1 colspan=1>Copan UniversalTransport Media(UTM)</td><td rowspan=1 colspan=1>Neg (3/3)</td><td rowspan=1 colspan=1>388 / 295</td><td rowspan=1 colspan=1>Flu A Pos(3/3)</td><td rowspan=1 colspan=1>1559</td><td rowspan=1 colspan=1>Flu A Pos(3/3)</td><td rowspan=1 colspan=1>2630</td><td rowspan=1 colspan=1>Flu B Pos(3/3)</td><td rowspan=1 colspan=1>1143</td><td rowspan=1 colspan=1>Flu B Pos(3/3)</td><td rowspan=1 colspan=1>1928</td></tr><tr><td rowspan=1 colspan=1>Remel M4 Media</td><td rowspan=1 colspan=1>Neg (3/3)</td><td rowspan=1 colspan=1>495 / 307</td><td rowspan=1 colspan=1>Flu A Pos(3/3)</td><td rowspan=1 colspan=1>1629</td><td rowspan=1 colspan=1>Flu A Pos(3/3)</td><td rowspan=1 colspan=1>3068</td><td rowspan=1 colspan=1>Flu B Pos(3/3)</td><td rowspan=1 colspan=1>1254</td><td rowspan=1 colspan=1>Flu B Pos(3/3)</td><td rowspan=1 colspan=1>2339</td></tr><tr><td rowspan=1 colspan=1>Remel M4-RT Media</td><td rowspan=1 colspan=1>Neg (3/3)</td><td rowspan=1 colspan=1>530 / 364</td><td rowspan=1 colspan=1>Flu A Pos(3/3)</td><td rowspan=1 colspan=1>1711</td><td rowspan=1 colspan=1>Flu A Pos(3/3)</td><td rowspan=1 colspan=1>2984</td><td rowspan=1 colspan=1>Flu B Pos(3/3)</td><td rowspan=1 colspan=1>1218</td><td rowspan=1 colspan=1>Flu B Pos(3/3)</td><td rowspan=1 colspan=1>2349</td></tr><tr><td rowspan=1 colspan=1>Remel M5 Media</td><td rowspan=1 colspan=1>Neg (3/3)</td><td rowspan=1 colspan=1>409 / 242</td><td rowspan=1 colspan=1>Flu A Pos(3/3)</td><td rowspan=1 colspan=1>1548</td><td rowspan=1 colspan=1>Flu A Pos(3/3)</td><td rowspan=1 colspan=1>2684</td><td rowspan=1 colspan=1>Flu B Pos(3/3)</td><td rowspan=1 colspan=1>1189</td><td rowspan=1 colspan=1>Flu B Pos(3/3)</td><td rowspan=1 colspan=1>1759</td></tr><tr><td rowspan=1 colspan=1>Starplex TransportMedia</td><td rowspan=1 colspan=1>Neg (3/3)</td><td rowspan=1 colspan=1>366 / 269</td><td rowspan=1 colspan=1>Flu A Pos(3/3)</td><td rowspan=1 colspan=1>1529</td><td rowspan=1 colspan=1>Flu A Pos(3/3)</td><td rowspan=1 colspan=1>2673</td><td rowspan=1 colspan=1>Flu B Pos(3/3)</td><td rowspan=1 colspan=1>1110</td><td rowspan=1 colspan=1>Flu B Pos(3/3)</td><td rowspan=1 colspan=1>1844</td></tr><tr><td rowspan=1 colspan=1>Phosphate BufferedSaline (PBS) Solution</td><td rowspan=1 colspan=1>Neg (3/3)</td><td rowspan=1 colspan=1>345 / 272</td><td rowspan=1 colspan=1>Flu A Pos(3/3)</td><td rowspan=1 colspan=1>1632</td><td rowspan=1 colspan=1>Flu A Pos(3/3)</td><td rowspan=1 colspan=1>2939</td><td rowspan=1 colspan=1>Flu B Pos(3/3)</td><td rowspan=1 colspan=1>1132</td><td rowspan=1 colspan=1>Flu B Pos(3/3)</td><td rowspan=1 colspan=1>2055</td></tr><tr><td rowspan=1 colspan=1>St. Louis Children&#x27;sHospital In-houseMedia</td><td rowspan=1 colspan=1>Neg (3/3)</td><td rowspan=1 colspan=1>319 / 306</td><td rowspan=1 colspan=1>Flu A Pos(3/3)</td><td rowspan=1 colspan=1>1684</td><td rowspan=1 colspan=1>Flu A Pos(3/3)</td><td rowspan=1 colspan=1>3297</td><td rowspan=1 colspan=1>Flu B Pos(3/3)</td><td rowspan=1 colspan=1>1371</td><td rowspan=1 colspan=1>Flu B Pos(3/3)</td><td rowspan=1 colspan=1>2309</td></tr><tr><td rowspan=1 colspan=1>Texas Children&#x27;sHospital In-houseMedia</td><td rowspan=1 colspan=1>Neg (3/3)</td><td rowspan=1 colspan=1>332 / 263</td><td rowspan=1 colspan=1>Flu A Pos(3/3)</td><td rowspan=1 colspan=1>1669</td><td rowspan=1 colspan=1>Flu A Pos(3/3)</td><td rowspan=1 colspan=1>2559</td><td rowspan=1 colspan=1>Flu B Pos(3/3)</td><td rowspan=1 colspan=1>1202</td><td rowspan=1 colspan=1>Flu B Pos(3/3)</td><td rowspan=1 colspan=1>2019</td></tr><tr><td rowspan=1 colspan=1>Total Mean RAMPRatio</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>398 / 290</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1620</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>2854</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1203</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>2075</td></tr><tr><td rowspan=1 colspan=1>RAMP Ratio SD</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>77 /37</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>258</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>83</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>232</td></tr><tr><td rowspan=1 colspan=1>RAMP Ratio % CV</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Flu A 19%Flu B 13%</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>4%</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>9%</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>7%</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>11%</td></tr></table>

# $j .$ . Sample Collection Swabs Compatibility:

Four swab materials were evaluated for compatibility in the RAMP Influenza $\mathrm { A } / \mathrm { B }$ Assay by testing a negative sample (swab alone with no virus present), an Influenza A LoD positive sample $( 3 0 0 ~ \mathrm { E I D 5 0 / m L }$ after extraction), an Influenza A 2x LoD positive sample ( $6 0 0 \mathrm { E I D } 5 0 / \mathrm { m L }$ after extraction), an Influenza B LoD positive sample $( 3 1 6 ~ \mathrm { E I D 5 0 / m L }$ after extraction), and an Influenza B $2 \mathbf { x }$ LoD positive sample $( 6 3 2 \mathrm { E I D } 5 0 / \mathrm { m L }$ after extraction) at $\mathrm { n } { = } 3$ replicates each in the RAMP Influenza A/B Assay. The influenza strains used to prepare the samples were Influenza A/Hong Kong/8/68 and Influenza B/Lee/40. These influenza strains were re-titered prior to swab testing. Each swab was dosed with $2 0 \mu \mathrm { L }$ of the appropriate sample and extracted into $3 ~ \mathrm { m L }$ Copan Universal Transport media by vortexing for 30 seconds to get the target concentration for each sample prior to testing in the RAMP Influenza A/B Assay. Each replicate tested was prepared from a separate swab. Swabs made of sterile foam, polyester, nylon, or rayon were evaluated. The RAMP Flu A/B assay is a qualitative assay based on numerical RAMP Ratio values. The $\% C V s$ were also calculated based on the RAMP Ratios for the testing

The negative sample (swab alone) tested negative. At least two of three of each swab type inoculated with Influenza A or Influenza B at the LoD tested positive for the virus.

<table><tr><td rowspan=3 colspan=1>Swab Material Tested</td><td rowspan=1 colspan=10>RAMP ResultsInfluenza A Threshold 1= 1023                               Influenza B Threshold 2= 649</td></tr><tr><td rowspan=1 colspan=2>Negative</td><td rowspan=1 colspan=2>Influenza A LoD</td><td rowspan=1 colspan=2>Influenza A 2x LoD</td><td rowspan=1 colspan=2>Influenza B LoD</td><td rowspan=1 colspan=2>Influenza B 2x LoD</td></tr><tr><td rowspan=1 colspan=1>Results</td><td rowspan=1 colspan=1>MeanRAMPRatioFluA/FluB</td><td rowspan=1 colspan=1>Results</td><td rowspan=1 colspan=1>MeanRAMPRat</td><td rowspan=1 colspan=1>Results</td><td rowspan=1 colspan=1>MeanRAMPRatio</td><td rowspan=1 colspan=1>Results</td><td rowspan=1 colspan=1>MeanRAMPRtio</td><td rowspan=1 colspan=1>Results</td><td rowspan=1 colspan=1>MeanRAMPRatio</td></tr><tr><td rowspan=1 colspan=1>Foam</td><td rowspan=1 colspan=1>Neg (3/3)</td><td rowspan=1 colspan=1>441 /231</td><td rowspan=1 colspan=1>Flu A Pos(3/3)</td><td rowspan=1 colspan=1>1392</td><td rowspan=1 colspan=1>Flu A Pos(3/3)</td><td rowspan=1 colspan=1>2354</td><td rowspan=1 colspan=1>Flu B Pos(3/3)</td><td rowspan=1 colspan=1>1171</td><td rowspan=1 colspan=1>Flu B Pos(3/3)</td><td rowspan=1 colspan=1>2194</td></tr><tr><td rowspan=1 colspan=1>Polyester</td><td rowspan=1 colspan=1>Neg (3/3)</td><td rowspan=1 colspan=1>370 / 228</td><td rowspan=1 colspan=1>Flu A Pos(2/3)</td><td rowspan=1 colspan=1>1116</td><td rowspan=1 colspan=1>Flu A Pos(3/3)</td><td rowspan=1 colspan=1>2342</td><td rowspan=1 colspan=1>Flu B Pos(2/3)</td><td rowspan=1 colspan=1>735</td><td rowspan=1 colspan=1>Flu B Pos(3/3)</td><td rowspan=1 colspan=1>1431</td></tr><tr><td rowspan=1 colspan=1>Rayon</td><td rowspan=1 colspan=1>Neg (3/3)</td><td rowspan=1 colspan=1>406 / 252</td><td rowspan=1 colspan=1>Flu A Pos(3/3)</td><td rowspan=1 colspan=1>1267</td><td rowspan=1 colspan=1>Flu A Pos(3/3)</td><td rowspan=1 colspan=1>2169</td><td rowspan=1 colspan=1>Flu B Pos(2/3)</td><td rowspan=1 colspan=1>661</td><td rowspan=1 colspan=1>Flu B Pos(3/3)</td><td rowspan=1 colspan=1>1342</td></tr><tr><td rowspan=1 colspan=1>Nylon</td><td rowspan=1 colspan=1>Neg (3/3)</td><td rowspan=1 colspan=1>543 / 353</td><td rowspan=1 colspan=1>Flu A Pos(3/3)</td><td rowspan=1 colspan=1>1581</td><td rowspan=1 colspan=1>Flu A Pos(3/3)</td><td rowspan=1 colspan=1>2629</td><td rowspan=1 colspan=1>Flu B Pos(3/3)</td><td rowspan=1 colspan=1>1147</td><td rowspan=1 colspan=1>Flu B Pos(3/3)</td><td rowspan=1 colspan=1>2002</td></tr><tr><td rowspan=1 colspan=1>Total Mean RAMPRatio</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>440 / 266</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1339</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>2374</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>928</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1742</td></tr><tr><td rowspan=1 colspan=1>RAMP Ratio SD</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>75 / 59</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>197</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>190</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>268</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>420</td></tr><tr><td rowspan=1 colspan=1>RAMP Ratio % CV</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Flu A 17%Flu B 22%</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>15%</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>8%</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>29%</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>24%</td></tr></table>

# k. Sample Stability Testing:

The RAMP Influenza $\mathrm { A } / \mathrm { B }$ Assay was evaluated to determine the effect of time of storage of the sample at $2 { - } 8 \mathrm { { ^ \circ C } }$ to assess stability of detection of the antigen in the sample. Clinical samples from the British Columbia Centre for Disease Control (BCCDC) equivalent to those tested in the clinical trial were thawed and diluted in viral transport media to simulate samples that were close to the Threshold 1 ratio values. The clinical samples were then tested immediately and after 72 hours storage at $2 \mathrm { { ^ \circ C } }$ and $8 \mathrm { ^ \circ C }$ .

The results indicate that samples tested in the RAMP Influenza A/B Assay are stable for at least 72 hours when stored at $2 { - } 8 \mathrm { { ^ \circ C } }$ .

<table><tr><td colspan="6" rowspan="1">Influenza A RAMP Ratio (Results)</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Time 0</td><td colspan="2" rowspan="1">72 hrs at 2</td><td colspan="2" rowspan="1">72 hrs at 8°C</td></tr><tr><td colspan="1" rowspan="1">Sample ID (dilution)P(BCDC)</td><td colspan="1" rowspan="1">Ratio (Result)</td><td colspan="1" rowspan="1">Ratio (Result)</td><td colspan="1" rowspan="1">Percent of Time 0Ratio</td><td colspan="1" rowspan="1">Ratio (Result)</td><td colspan="1" rowspan="1">Percent of Time 0Ratio</td></tr><tr><td colspan="1" rowspan="1">A5VI 27170-A (1/20)</td><td colspan="1" rowspan="1">1556 (Flu A Pos)</td><td colspan="1" rowspan="1">1816 (Flu A Pos)</td><td colspan="1" rowspan="1">117</td><td colspan="1" rowspan="1">1486 (Flu A Pos)</td><td colspan="1" rowspan="1">96</td></tr><tr><td colspan="1" rowspan="1">A5VI 27597-A (1/6)</td><td colspan="1" rowspan="1">2466 (Flu A Pos)</td><td colspan="1" rowspan="1">2883 (Flu A Pos)</td><td colspan="1" rowspan="1">117</td><td colspan="1" rowspan="1">2480 (Flu A Pos)</td><td colspan="1" rowspan="1">101</td></tr><tr><td colspan="1" rowspan="1">A6VI 01262-B (1/6)</td><td colspan="1" rowspan="1">364 (Negative)</td><td colspan="1" rowspan="1">406 (Negative)</td><td colspan="1" rowspan="1">112</td><td colspan="1" rowspan="1">339 (Negative)</td><td colspan="1" rowspan="1">93</td></tr><tr><td colspan="1" rowspan="1">A5VI 27163-A (1/10)</td><td colspan="1" rowspan="1">1016 (Flu A Pos)</td><td colspan="1" rowspan="1">948 (Flu A Pos)</td><td colspan="1" rowspan="1">93</td><td colspan="1" rowspan="1">1094 (Flu A Pos)</td><td colspan="1" rowspan="1">108</td></tr><tr><td colspan="1" rowspan="1">A5VI 27308-A (1/10)</td><td colspan="1" rowspan="1">1289 (Flu A Pos)</td><td colspan="1" rowspan="1">1224 (Flu A Pos)</td><td colspan="1" rowspan="1">95</td><td colspan="1" rowspan="1">1216 (Flu A Pos)</td><td colspan="1" rowspan="1">94</td></tr><tr><td colspan="1" rowspan="1">A5VI 27606-A (1/40)</td><td colspan="1" rowspan="1">1943 (Flu A Pos)</td><td colspan="1" rowspan="1">2241 (Flu A Pos)</td><td colspan="1" rowspan="1">115</td><td colspan="1" rowspan="1">2016 (Flu A Pos)</td><td colspan="1" rowspan="1">104</td></tr><tr><td colspan="1" rowspan="1">A5VI 27559-A (1/20)</td><td colspan="1" rowspan="1">2576 (Flu A Pos)</td><td colspan="1" rowspan="1">2873 (Flu A Pos)</td><td colspan="1" rowspan="1">112</td><td colspan="1" rowspan="1">3033 (Flu A Pos)</td><td colspan="1" rowspan="1">118</td></tr><tr><td colspan="1" rowspan="1">A5VI 27562-A (1/20)</td><td colspan="1" rowspan="1">1710 (Flu A Pos)</td><td colspan="1" rowspan="1">1720 (Flu A Pos)</td><td colspan="1" rowspan="1">101</td><td colspan="1" rowspan="1">1777 (Flu A Pos)</td><td colspan="1" rowspan="1">104</td></tr><tr><td colspan="1" rowspan="1">A5VI 27213-A (1/10)</td><td colspan="1" rowspan="1">706 (Negative)</td><td colspan="1" rowspan="1">980 (Flu A Pos)</td><td colspan="1" rowspan="1">139</td><td colspan="1" rowspan="1">976 (Flu A Pos)</td><td colspan="1" rowspan="1">138</td></tr><tr><td colspan="1" rowspan="1">A5VI 27349-A (1/10)</td><td colspan="1" rowspan="1">446 (Negative)</td><td colspan="1" rowspan="1">437 (Negative)</td><td colspan="1" rowspan="1">98</td><td colspan="1" rowspan="1">413 (Negative)</td><td colspan="1" rowspan="1">93</td></tr><tr><td colspan="1" rowspan="1">10008549 (1/20)</td><td colspan="1" rowspan="1">374 (Negative)</td><td colspan="1" rowspan="1">460 (Negative)</td><td colspan="1" rowspan="1">123</td><td colspan="1" rowspan="1">400 (Negative)</td><td colspan="1" rowspan="1">107</td></tr><tr><td colspan="1" rowspan="1">10008549 (1/40)</td><td colspan="1" rowspan="1">320 (Negative)</td><td colspan="1" rowspan="1">394 (Negative)</td><td colspan="1" rowspan="1">123</td><td colspan="1" rowspan="1">416 (Negative)</td><td colspan="1" rowspan="1">130</td></tr><tr><td colspan="1" rowspan="1">10017303 (1/20)</td><td colspan="1" rowspan="1">443 (Negative)</td><td colspan="1" rowspan="1">490 (Negative)</td><td colspan="1" rowspan="1">111</td><td colspan="1" rowspan="1">375 (Negative)</td><td colspan="1" rowspan="1">85</td></tr><tr><td colspan="1" rowspan="1">10041464 (1/6)</td><td colspan="1" rowspan="1">411 (Negative)</td><td colspan="1" rowspan="1">378 (Negative)</td><td colspan="1" rowspan="1">92</td><td colspan="1" rowspan="1">382 (Negative)</td><td colspan="1" rowspan="1">93</td></tr><tr><td colspan="1" rowspan="1">10045523 (1/6)</td><td colspan="1" rowspan="1">438 (Negative)</td><td colspan="1" rowspan="1">440 (Negative)</td><td colspan="1" rowspan="1">101</td><td colspan="1" rowspan="1">331 (Negative)</td><td colspan="1" rowspan="1">76</td></tr><tr><td colspan="1" rowspan="1">10008549 (1/80)</td><td colspan="1" rowspan="1">385 (Negative)</td><td colspan="1" rowspan="1">293 (Negative)</td><td colspan="1" rowspan="1">76</td><td colspan="1" rowspan="1">473 (Negative)</td><td colspan="1" rowspan="1">123</td></tr><tr><td colspan="1" rowspan="1">Mean % Recovery</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">108</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">104</td></tr><tr><td colspan="6" rowspan="1">Influenza B RAMP Ratio (Results)</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Time 0</td><td colspan="2" rowspan="1">72 hrs at 2°C</td><td colspan="2" rowspan="1">72 hrs at 8°C</td></tr><tr><td colspan="1" rowspan="1">Sample ID (dilution)(BCCDC)</td><td colspan="1" rowspan="1">Ratio (Result)</td><td colspan="1" rowspan="1">Ratio (Result)</td><td colspan="1" rowspan="1">Percent of Time 0Ratio</td><td colspan="1" rowspan="1">Ratio (Result)</td><td colspan="1" rowspan="1">Percent of Time 0Ratio</td></tr><tr><td colspan="1" rowspan="1">A5VI 27170-A (1/20)</td><td colspan="1" rowspan="1">186 (Negative)</td><td colspan="1" rowspan="1">108 (Negative)</td><td colspan="1" rowspan="1">58</td><td colspan="1" rowspan="1">181 (Negative)</td><td colspan="1" rowspan="1">97</td></tr><tr><td colspan="1" rowspan="1">A5VI 27597-A (1/6)</td><td colspan="1" rowspan="1">250 (Negative)</td><td colspan="1" rowspan="1">246 (Negative)</td><td colspan="1" rowspan="1">98</td><td colspan="1" rowspan="1">129 (Negative)</td><td colspan="1" rowspan="1">52</td></tr><tr><td colspan="1" rowspan="1">A6VI 01262-B (1/6)</td><td colspan="1" rowspan="1">668 (Flu B Pos)</td><td colspan="1" rowspan="1">516 (Flu B Pos)</td><td colspan="1" rowspan="1">77</td><td colspan="1" rowspan="1">713 (Flu B Pos)</td><td colspan="1" rowspan="1">107</td></tr><tr><td colspan="1" rowspan="1">A5VI 27163-A (1/10)</td><td colspan="1" rowspan="1">209 (Negative)</td><td colspan="1" rowspan="1">143 (Negative)</td><td colspan="1" rowspan="1">68</td><td colspan="1" rowspan="1">137 (Negative)</td><td colspan="1" rowspan="1">66</td></tr><tr><td colspan="1" rowspan="1">A5VI 27308-A (1/10)</td><td colspan="1" rowspan="1">259 (Negative)</td><td colspan="1" rowspan="1">136 (Negative)</td><td colspan="1" rowspan="1">53</td><td colspan="1" rowspan="1">228 (Negative)</td><td colspan="1" rowspan="1">88</td></tr><tr><td colspan="1" rowspan="1">A5VI 27606-A (1/40)</td><td colspan="1" rowspan="1">155 (Negative)</td><td colspan="1" rowspan="1">168 (Negative)</td><td colspan="1" rowspan="1">108</td><td colspan="1" rowspan="1">164 (Negative)</td><td colspan="1" rowspan="1">106</td></tr><tr><td colspan="1" rowspan="1">A5VI 27559-A (1/20)</td><td colspan="1" rowspan="1">129 (Negative)</td><td colspan="1" rowspan="1">233 (Negative)</td><td colspan="1" rowspan="1">181</td><td colspan="1" rowspan="1">236 (Negative)</td><td colspan="1" rowspan="1">183</td></tr><tr><td colspan="1" rowspan="1">A5VI 27562-A (1/20)</td><td colspan="1" rowspan="1">264 (Negative)</td><td colspan="1" rowspan="1">248 (Negative)</td><td colspan="1" rowspan="1">94</td><td colspan="1" rowspan="1">150 (Negative)</td><td colspan="1" rowspan="1">57</td></tr><tr><td colspan="1" rowspan="1">A5VI 27213-A (1/10)</td><td colspan="1" rowspan="1">119 (Negative)</td><td colspan="1" rowspan="1">148 (Negative)</td><td colspan="1" rowspan="1">124</td><td colspan="1" rowspan="1">193 (Negative)</td><td colspan="1" rowspan="1">162</td></tr><tr><td colspan="1" rowspan="1">A5VI 27349-A (1/10)</td><td colspan="1" rowspan="1">182 (Negative)</td><td colspan="1" rowspan="1">93 (Negative)</td><td colspan="1" rowspan="1">51</td><td colspan="1" rowspan="1">223 (Negative)</td><td colspan="1" rowspan="1">123</td></tr><tr><td colspan="1" rowspan="1">10008549 (1/20)</td><td colspan="1" rowspan="1">2657 (Flu B Pos)</td><td colspan="1" rowspan="1">2825 (Flu B Pos)</td><td colspan="1" rowspan="1">106</td><td colspan="1" rowspan="1">2945 (Flu B Pos)</td><td colspan="1" rowspan="1">111</td></tr><tr><td colspan="1" rowspan="1">10008549 (1/40)</td><td colspan="1" rowspan="1">1215 (Flu B Pos)</td><td colspan="1" rowspan="1">1468 (Flu B Pos)</td><td colspan="1" rowspan="1">121</td><td colspan="1" rowspan="1">1433 (Flu B Pos)</td><td colspan="1" rowspan="1">118</td></tr><tr><td colspan="1" rowspan="1">10017303 (1/20)</td><td colspan="1" rowspan="1">443 (Negative)</td><td colspan="1" rowspan="1">518 (Flu B Pos)</td><td colspan="1" rowspan="1">117</td><td colspan="1" rowspan="1">474 (Flu B Pos)</td><td colspan="1" rowspan="1">107</td></tr><tr><td colspan="1" rowspan="1">10041464 (1/6)</td><td colspan="1" rowspan="1">110 (Negative)</td><td colspan="1" rowspan="1">137 (Negative)</td><td colspan="1" rowspan="1">125</td><td colspan="1" rowspan="1">176 (Negative)</td><td colspan="1" rowspan="1">160</td></tr><tr><td colspan="1" rowspan="1">10045523 (1/6)</td><td colspan="1" rowspan="1">150 (Negative)</td><td colspan="1" rowspan="1">111 (Negative)</td><td colspan="1" rowspan="1">74</td><td colspan="1" rowspan="1">223 (Negative)</td><td colspan="1" rowspan="1">149</td></tr><tr><td colspan="1" rowspan="1">10008549 (1/80)</td><td colspan="1" rowspan="1">684 (Flu B Pos)</td><td colspan="1" rowspan="1">700 (Flu B Pos)</td><td colspan="1" rowspan="1">102</td><td colspan="1" rowspan="1">861 (Flu B Pos)</td><td colspan="1" rowspan="1">126</td></tr><tr><td colspan="1" rowspan="1">Mean % Recovery</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">97</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">113</td></tr></table>

2. Comparison studies:

a. Method comparison with predicate device: Not applicable.   
b. Matrix comparison: Not applicable.

3. Clinical studies:

# a. Prospective Clinical studies

The performance of the RAMP Influenza A/B Assay was compared to cell culture in a prospective study conducted as part of a multi-center trial in North America during the 2006-2007 influenza season when influenza $\mathrm { A } / \mathrm { H } 3$ $( 3 6 . 5 \% )$ and $\mathrm { A } / \mathrm { H } 1$ $( 6 3 . 5 \% )$ were the predominant Influenza A viruses in circulation1 . Four independent laboratories (located in distinct geographic regions) evaluated the RAMP Influenza A/B Assay in parallel with cell culture. Eight hundred Forty-four (844) fresh specimens (nasal wash/aspirate, nasopharyngeal aspirate, or nasopharyngeal swab samples) prospectively collected during the 2006-2007 influenza season were tested. Across the sites these samples were drawn from an approximately equal mix of pediatric $( 0 - 2 1$ years) and adult patients $( 2 1 +$ years) with approximately equal numbers of male and female patients. The mean (standard deviation) age of the patients was 28.6 (30.7) years. The results of the prospective clinical trials based on sample type are given in the following tables:

<table><tr><td rowspan=1 colspan=1>Prospective FreshNasopharyngealSwab</td><td rowspan=1 colspan=3>RAMP Influenza A</td><td rowspan=1 colspan=3>RAMP Influenza B</td></tr><tr><td rowspan=1 colspan=1>Tissue Culture</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>53</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>12</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>541</td><td rowspan=1 colspan=1>560</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>602</td><td rowspan=1 colspan=1>614</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>554</td><td rowspan=1 colspan=1>626</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>607</td><td rowspan=1 colspan=1>626</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>53/66</td><td rowspan=1 colspan=1>80.3%</td><td rowspan=1 colspan=1>68.7-89.1%</td><td rowspan=1 colspan=1>7/12</td><td rowspan=1 colspan=1>58.3%</td><td rowspan=1 colspan=1>27.7-84.8%</td></tr><tr><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1>541/560</td><td rowspan=1 colspan=1>96.6%</td><td rowspan=1 colspan=1>94.8-97.9%</td><td rowspan=1 colspan=1>602/614</td><td rowspan=1 colspan=1>98.0%</td><td rowspan=1 colspan=1>96.6-99.0%</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Prospective FreshNasalWash/Aspirate</td><td rowspan=1 colspan=3>RAMP Influenza A</td><td rowspan=1 colspan=3>RAMP Influenza B</td></tr><tr><td rowspan=1 colspan=1>Tissue Culture</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>9</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>162</td><td rowspan=1 colspan=1>173</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>207</td><td rowspan=1 colspan=1>209</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>171</td><td rowspan=1 colspan=1>218</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>207</td><td rowspan=1 colspan=1>218</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>36/45</td><td rowspan=1 colspan=1>80.0%</td><td rowspan=1 colspan=1>65.4-90.4%</td><td rowspan=1 colspan=1>9/9</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>66.4-100%</td></tr><tr><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1>162/173</td><td rowspan=1 colspan=1>93.6%</td><td rowspan=1 colspan=1>88.9-96.8%</td><td rowspan=1 colspan=1>207/209</td><td rowspan=1 colspan=1>99.0%</td><td rowspan=1 colspan=1>96.6-99.9%</td></tr></table>

The results of the prospective clinical trials based on sample type and stratified by patient age group are given in the following tables:

<table><tr><td rowspan=1 colspan=1>Prospective FreshNasopharyngealSwab(Age 0-5)</td><td rowspan=1 colspan=3>RAMP Influenza A</td><td rowspan=1 colspan=3>RAMP Influenza B</td></tr><tr><td rowspan=1 colspan=1>Tissue Culture</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>187</td><td rowspan=1 colspan=1>199</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>204</td><td rowspan=1 colspan=1>210</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>188</td><td rowspan=1 colspan=1>211</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>204</td><td rowspan=1 colspan=1>211</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>11/12</td><td rowspan=1 colspan=1>91.7%</td><td rowspan=1 colspan=1>61.5-99.8%</td><td rowspan=1 colspan=1>1/1</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1>187/199</td><td rowspan=1 colspan=1>94.0%</td><td rowspan=1 colspan=1>89.7%-96.8%</td><td rowspan=1 colspan=1>204/210</td><td rowspan=1 colspan=1>97.1%</td><td rowspan=1 colspan=1>93.9-98.9%</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Prospective FreshNasopharyngealSwab(Age 6-21)</td><td rowspan=1 colspan=3>RAMP Influenza A</td><td rowspan=1 colspan=3>RAMP Influenza B</td></tr><tr><td rowspan=1 colspan=1>Tissue Culture</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>4</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>77</td><td rowspan=1 colspan=1>81</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>85</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>79</td><td rowspan=1 colspan=1>85</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>12/15</td><td rowspan=1 colspan=1>80.0%</td><td rowspan=1 colspan=1>51.9-95.7%</td><td rowspan=1 colspan=1>2/4</td><td rowspan=1 colspan=1>50.0%</td><td rowspan=1 colspan=1>6.8-93.2%</td></tr><tr><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1>66/70</td><td rowspan=1 colspan=1>94.3%</td><td rowspan=1 colspan=1>86.0-98.4%</td><td rowspan=1 colspan=1>77/81</td><td rowspan=1 colspan=1>95.1%</td><td rowspan=1 colspan=1>87.8-98.6%</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Prospective FreshNasopharyngealSwab(Age 22-59)</td><td rowspan=1 colspan=3>RAMP Influenza A</td><td rowspan=1 colspan=3>RAMP Influenza B</td></tr><tr><td rowspan=1 colspan=1>Tissue Culture</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>4</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>136</td><td rowspan=1 colspan=1>137</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>155</td><td rowspan=1 colspan=1>156</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>143</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>157</td><td rowspan=1 colspan=1>160</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>16/23</td><td rowspan=1 colspan=1>69.6%</td><td rowspan=1 colspan=1>47.1-86.8%</td><td rowspan=1 colspan=1>2/4</td><td rowspan=1 colspan=1>50.0%</td><td rowspan=1 colspan=1>6.8-93.2%</td></tr><tr><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1>136/137</td><td rowspan=1 colspan=1>99.3%</td><td rowspan=1 colspan=1>96.0-100%</td><td rowspan=1 colspan=1>155/156</td><td rowspan=1 colspan=1>99.4%</td><td rowspan=1 colspan=1>96.5-100%</td></tr></table>

<table><tr><td colspan="1" rowspan="1">Prospective FreshNasopharyngeal Swab(Age &gt;=60)</td><td colspan="3" rowspan="1">RAMP Influenza A</td><td colspan="3" rowspan="1">RAMP Influenza B</td></tr><tr><td colspan="1" rowspan="1">Tissue Culture</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Total</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Total</td></tr><tr><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">3</td></tr><tr><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">152</td><td colspan="1" rowspan="1">154</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">166</td><td colspan="1" rowspan="1">167</td></tr><tr><td colspan="1" rowspan="1">Total</td><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1">154</td><td colspan="1" rowspan="1">170</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">167</td><td colspan="1" rowspan="1">170</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">95% CI</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">95% CI</td></tr><tr><td colspan="1" rowspan="1">Sensitivity</td><td colspan="1" rowspan="1">14/16</td><td colspan="1" rowspan="1">87.5%</td><td colspan="1" rowspan="1">61.7-98.4%</td><td colspan="1" rowspan="1">2/3</td><td colspan="1" rowspan="1">66.7%</td><td colspan="1" rowspan="1">9.4-99.2%</td></tr><tr><td colspan="1" rowspan="1">Specificity</td><td colspan="1" rowspan="1">152/154</td><td colspan="1" rowspan="1">98.7%</td><td colspan="1" rowspan="1">95.4-99.8%</td><td colspan="1" rowspan="1">166/167</td><td colspan="1" rowspan="1">99.4%</td><td colspan="1" rowspan="1">96.7-100%</td></tr><tr><td colspan="1" rowspan="1">Prospective FreshNasal Wash/Aspirate(Age 0-5)</td><td colspan="3" rowspan="1">RAMP Influenza A</td><td colspan="3" rowspan="1">RAMP Influenza B</td></tr><tr><td colspan="1" rowspan="1">Tissue Culture</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Total</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Total</td></tr><tr><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">24</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">28</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">6</td></tr><tr><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">117</td><td colspan="1" rowspan="1">123</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">144</td><td colspan="1" rowspan="1">145</td></tr><tr><td colspan="1" rowspan="1">Total</td><td colspan="1" rowspan="1">30</td><td colspan="1" rowspan="1">121</td><td colspan="1" rowspan="1">151</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">144</td><td colspan="1" rowspan="1">151</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">95% CI</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">95% CI</td></tr><tr><td colspan="1" rowspan="1">Sensitivity</td><td colspan="1" rowspan="1">24/28</td><td colspan="1" rowspan="1">85.7%</td><td colspan="1" rowspan="1">67.3-96.0%</td><td colspan="1" rowspan="1">6/6</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">54.1-100%</td></tr><tr><td colspan="1" rowspan="1">Specificity</td><td colspan="1" rowspan="1">117/123</td><td colspan="1" rowspan="1">95.1%</td><td colspan="1" rowspan="1">89.7-98.2%</td><td colspan="1" rowspan="1">144/145</td><td colspan="1" rowspan="1">99.3%</td><td colspan="1" rowspan="1">96.2-100%</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Prospective FreshNasal Wash/Aspirate(Age 6-21)</td><td rowspan=1 colspan=3>RAMP Influenza A</td><td rowspan=1 colspan=3>RAMP Influenza B</td></tr><tr><td rowspan=1 colspan=1>Tissue Culture</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>41</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>60</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>63</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>12/17</td><td rowspan=1 colspan=1>70.6%</td><td rowspan=1 colspan=1>44.0-89.7%</td><td rowspan=1 colspan=1>3/3</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>29.2-100%</td></tr><tr><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1>41/46</td><td rowspan=1 colspan=1>89.1%</td><td rowspan=1 colspan=1>76.4-96.4%</td><td rowspan=1 colspan=1>59/60</td><td rowspan=1 colspan=1>98.3%</td><td rowspan=1 colspan=1>91.1-100%</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Prospective FreshNasal Wash/Aspirate(Age 22-59)</td><td rowspan=1 colspan=3>RAMP Influenza A</td><td rowspan=1 colspan=3>RAMP Influenza B</td></tr><tr><td rowspan=1 colspan=1>Tissue Culture</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>0/0</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>0/0</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1>3/3</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>29.2-100%</td><td rowspan=1 colspan=1>3/3</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>29.2-100%</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Prospective FreshNasal Wash/Aspirate(Age &gt;=60)</td><td rowspan=1 colspan=3>RAMP Influenza A</td><td rowspan=1 colspan=3>RAMP Influenza B</td></tr><tr><td rowspan=1 colspan=1>Tissue Culture</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>0/0</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>0/0</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1>1/1</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>1/1</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>NA</td></tr></table>

# b. Retrospective Clinical studies

In order to supplement the prospective study, performance of the RAMP Influenza A/B Test was also evaluated by two independent laboratories comparing to the original cell culture testing results (cell culture testings were performed originally using fresh specimens) on 75 retrospective frozen clinical nasopharyngeal swab samples and 130 retrospective frozen clinical wash/aspirate samples. The results of the retrospective clinical trials based on sample type are given in the following tables:

<table><tr><td rowspan=1 colspan=1>RetrospectiveFrozenNasopharyngealSwab</td><td rowspan=1 colspan=3>RAMP Influenza A</td><td rowspan=1 colspan=3>RAMP Influenza B</td></tr><tr><td rowspan=1 colspan=1>Tissue Culture</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>30</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>45</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>64</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>75</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Positive PercentAgreement</td><td rowspan=1 colspan=1>11/13</td><td rowspan=1 colspan=1>84.6%</td><td rowspan=1 colspan=1>54.5-98.1 %</td><td rowspan=1 colspan=1>23/30</td><td rowspan=1 colspan=1>76.7%</td><td rowspan=1 colspan=1>57.7-90.1%</td></tr><tr><td rowspan=1 colspan=1>Negative PercentAgreement</td><td rowspan=1 colspan=1>62/62</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>94.2-100%</td><td rowspan=1 colspan=1>45/45</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>92.1-100%</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Retrospective FrozenNasal Wash/Aspirate</td><td rowspan=1 colspan=3>RAMP Influenza A</td><td rowspan=1 colspan=3>RAMP Influenza B</td></tr><tr><td rowspan=1 colspan=1>Tissue Culture</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>39</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>83</td><td rowspan=1 colspan=1>85</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>89</td><td rowspan=1 colspan=1>91</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>93</td><td rowspan=1 colspan=1>130</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>95</td><td rowspan=1 colspan=1>130</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Positive PercentAgreement</td><td rowspan=1 colspan=1>35/45</td><td rowspan=1 colspan=1>77.8%</td><td rowspan=1 colspan=1>62.9-88.8%</td><td rowspan=1 colspan=1>33/39</td><td rowspan=1 colspan=1>84.6%</td><td rowspan=1 colspan=1>69.5-94.1%</td></tr><tr><td rowspan=1 colspan=1>Negative PercentAgreement</td><td rowspan=1 colspan=1>83/85</td><td rowspan=1 colspan=1>97.6%</td><td rowspan=1 colspan=1>91.8-99.7%</td><td rowspan=1 colspan=1>89/91</td><td rowspan=1 colspan=1>97.8%</td><td rowspan=1 colspan=1>92.3%-99.7%</td></tr></table>

c. Other clinical supportive data (when a. and b. are not applicable): Not applicable.

4. Clinical cut-off: Not applicable.

5. Expected values/Reference range:

The prevalence of Influenza varies each year with epidemics occurring during the fall and winter months in the US. Variables that affect the rate of positivity observed in respiratory testing include: the efficiency and timing of specimen collection, handling and transport of the specimen, the time of year, age of the patient, and local disease prevalence. During the 2006-2007 US respiratory season, the combined prevalence of Influenza A and Influenza B was $1 3 . 2 \% ^ { 1 }$ . In the 2007 RAMP Influenza $\mathrm { A } / \mathrm { B }$ multi-center clinical study (samples collected between January and April), the prevalence as observed with culture of Influenza A was $1 3 . 2 \%$ (111/844), Influenza B was $2 . 5 \%$ (21/844).

# N. Instrument Name:

RAMP $\textsuperscript { \textregistered }$ 200 reader

# O. System Descriptions:

# 1. Modes of Operation:

The ${ \mathrm { R A M P } } ^ { \mathrm { \textregistered } }$ 200 measures the amount of fluorescence emitted by antibody/antigen complexes bound at two detection zones (Influenza A and Influenza B) and at the internal standard zone. The $\mathrm { R A M P } ^ { \textregistered } 2 0 0$ calculates a ratio (RAMP Ratio) using the fluorescence reading of each detection zone (A and B) and the internal zone. The reader compares these ratios to predefined threshold limits to determine a positive or negative result for Influenza A and Influenza B in the tested sample.

# 2. Software:

FDA has reviewed applicant’s Hazard Analysis and software development processes for this line of product types:

Yes __ _X_ ___ or No

3. Specimen Identification: User enters Patient ID/Sample ID using either the touch screen of the Control Module or optional barcode scanner.

4. Specimen Sampling and Handling: Not applicable

5. Calibration:

Each box of test strips is supplied with a Lot Card containing the calibration information for each specific manufacturing lot. The Reader determines the lot information by reading the barcode on the bottom of each Test Cartridge and reports the result based on the fluorescence ratio calculated for the Cartridge and comparing it to the specific lot information loaded into the memory from the associated Lot Card.

# 6. Quality Control:

When the $\mathrm { R A M P } ^ { \textregistered } 2 0 0$ is turned on, it performs a Self-Test which verifies the system calibration, the cartridge transport mechanism and the Reader optics. During the self-test the system also determines remaining battery power, verifies the system clock and verifies the instrument calibration. In addition, the RAMP® 200 has an Internal Quality Control (IQC) function. IQC can be scheduled to be performed at a pre-specified interval (1-24 hours) and takes less than 1 minute to complete. The IQC function repeats all the start-up checks and ensures appropriate instrument operation.

The RAMP® 200 scans the entire length of the Assay strip within the Cartridge. There are 2 areas on the strip to which the fluorescently labeled antibodies bind, the “detection zone” and the “internal standard zone”. The Reader monitors the sample flow across the length of the Assay Strip. Should an operator delay for too long between loading the sample and inserting the Cartridge into the Reader, insert a Cartridge that has already been run, apply too little sample to the Cartridge, or not use the supplied Assay Tip from the kit Pouch, the flow detected will not adhere to expected patterns and an error will be reported. In this way each Cartridge assures appropriate operator technique. Prior to reporting a result, the Reader software checks that the background signal (measured from areas outside of the detection zone and internal standard zones) is not higher than a predetermined value and that the total amount of fluorescence is above a predefined value. If either of these parameters is not met, an error is reported.

# P. Other Supportive Instrument Performance Characteristics Data Not Covered In The “Performance Characteristics” Section above:

Not applicable

# Q. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# R. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.